Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?

Kou, Pei, Wei, Shuang, Xiong, Fei · 2019 · Current Medicinal Chemistry

Abstract

Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common monogenic kidney disease, is caused by mutations in the PKD1, PKD2 or, in a very limited number of families, GANAB genes. Although cellular and molecular mechanisms of this disease have been understood in the past 20 years, specific therapy approaches remain very little. Both experimental and clinical studies show that the mammalian or mechanistic target of rapamycin (mTOR) pathway plays an important role during cyst formation and enlargement in ADPKD. Studies in rodent models of ADPKD showed that mTOR inhibitors had a significant and long-lasting decrease in kidney volume and amelioration in kidney function. In the past over ten years, researchers have been devoting continuously to test mTOR inhibitors efficacy and safety in both preclinical studies and clinical trials in patients with ADPKD. In this review, we will discuss the mTOR pathway thoroughly, mainly focusing on current advances in understanding its role in ADPKD, especially the recent progress of mTOR inhibitors use in preclinical studies and clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.2174/0929867325666180330094434

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Cited by

See all 6

Metadata

Authors
Kou, P., Wei, S., & Xiong, F.
Affiliations
  • Wuhan No.1 Hospital (CN)
  • Tongji Hospital (CN)
Corresponding author
  • Wei, Shuang
  • Xiong, Fei
Venue
Current Medicinal Chemistry
Published
2019-08-26
Volume
26
Issue
16
Pages
2962-2973
ISSN
0929-8673 (ISSN-L)
OpenAlex
W2795093309
Cited by
6
References
65
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2021: 2 · 2020: 1
FWCI
0.10
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81772477)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
autosomal dominant polycystic kidney disease, mTOR inhibitors, mTOR signaling, PKD1, PKD2, GANAB, cyst formation, kidney volume, renal function, preclinical research, clinical trials, drug safety
MeSH terms
Animals, Clinical Trials as Topic, Humans, Polycystic Kidney, Autosomal Dominant, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? https://app.cochat.ai/papers/10.2174/0929867325666180330094434
The paper
Kou, P., Wei, S., & Xiong, F. (2019). Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? Current Medicinal Chemistry. https://doi.org/10.2174/0929867325666180330094434

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.